S
Sensius
Sensius is focused on establishing thermotherapy as a key treatment modality for cancer patients alongside radiotherapy, surgery, chemotherapy, and immunotherapy
About Sensius
Sensius is a healthcare startup that specializes in thermotherapy treatments for cancer patients. The company operates within the medical technology market, specifically focusing on cancer treatment. Their innovative approach combines traditional therapies such as radiotherapy, chemotherapy, and immunotherapy with thermotherapy, a process that involves heating the tumor to 42 degrees Celsius. This method has been shown to improve clinical outcomes and reduce toxicity, thereby enhancing the quality of life for patients and reducing overall treatment costs.
Read full description
Sensius' business model revolves around the development and distribution of their patented technology, which allows for the controlled heating of deep-seated tumors while preserving surrounding tissues and organs. This technology not only provides high performance in focus and control of the heat, but also integrates seamlessly with the existing radiotherapy workflow, making it an attractive option for clinics. The company generates revenue by selling this technology to healthcare providers worldwide.
The company has positioned itself as a leader in thermotherapy through continuous research and collaboration with renowned clinical teams globally. This commitment to innovation and quality has earned the endorsement of key opinion leaders in the field.
In summary, Sensius is a promising startup in the medical technology sector, offering a unique and effective solution for cancer treatment that improves patient outcomes and reduces healthcare costs.
At a glance
- Status
- Operational
- Founded
- 2015
- Headquarters
- Rotterdam, Netherlands
- Employees
- 13
- Open positions
- 1
- Dealroom signal
- 83.3/100
- Industry
- Health
- Sub-industry
- BioTechnology, Medical Devices
- Sector
- Biotech & Life Sciences, Biotechnology, Oncology, Spinout, Sustainable Development Goals, EIC
- Technology
- Hardware, 3D Technology, Big Data, Deep Tech
- Business model
- Manufacturing
- Client focus
- b2b
Latest news
Press, funding announcements and product moves mentioning Sensius.
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| EARLY VC✓Equity / VC | Jun 2025 | $17M | $66M | UCEA Capital Partners · GrayBella Capital · EIC Fund | ↗ |
| EARLY VC✓Equity / VC | Jan 2023 | $7.4M | $29M | EIC Fund | ↗ |
Growth signals
Latest recorded traffic for Sensius is 10 monthly website visits, down 50% over the last three months. Sensius's team declined 7.1% over the past year.
Open positions
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Seed4 investors entered at this stage
UNIIQ
Rabobank
European Innovation Council- ANAngels
Series A3 investors entered at this stage
EIC Fund
UCEA Capital Partners
GrayBella Capital
Other known investors5 additional known investors
EIT Health
Erasmus University Medical Center
Erasmus University Rotterdam
InnovationQuarter Capital
Negma Group
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about Sensius on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Sensius’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.